Glaukos Announces Participation In Piper Jaffray Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 28 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016, at 12:00 p.m. EST in New York City.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.

About Glaukos

Glaukos ( www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world's leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent ® , its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161116006500/en/
Copyright Business Wire 2010

If you liked this article you might like

Mad Money Lightning Round: Chevron, American Electric Power, Wendy's
Jim Cramer's 'Mad Money' Recap: Tech and Natural Resources Both Gain

Jim Cramer's 'Mad Money' Recap: Tech and Natural Resources Both Gain

8 Stocks Spiking on Big Volume

8 Stocks Spiking on Big Volume

5 Breakout Stocks for Your Buy List

5 Breakout Stocks for Your Buy List

Buy These 5 Breakout Stocks Now for Big Gains

Buy These 5 Breakout Stocks Now for Big Gains